ANGLE PLC (LON:AGL) has noted the results of new research from the Laboratory of Translational Oncology, School of Medicine, University of Crete, which demonstrated the potential of its Parsortix liquid biopsy system to assess whether non-small cell lung cancer (NSCLC) patients will respond to immunotherapy drugs.
The AIM-listed firm said the study had combined an assessment of immunotherapy drugs known as PD-L1 immune checkpoint inhibitors, a novel treatment offered to patients with certain advanced cancers, with a second immune checkpoint, Indolamine-2,3-dioxygenase (IDO), on a patient's circulating tumour cells (CTCs).
ANGLE said the study demonstrated that the detection of IDO and CTCs, particularly of the IDO+/PD-L1- CTC subpopulation harvested using Parsortix, is significantly associated with reduced progression-free survival and overall survival in NSCLC patients treated with anti-PD-1 agents.
The company noted that while a variety of CTC systems and approaches were evaluated in the study, only CTC detection using its Parsortix system was “significantly associated with disease progression”.
“We have shown that, using ANGLE's Parsortix system, it is possible to assess both PD-L1 and IDO expression on the CTCs to give a prognostic indicator of whether patients will respond to immunotherapy drugs”, Sofia Agelaki, Associate Professor in Medical Oncology at the University of Crete said in a statement.
“Our findings stem from the evaluation of a small group of patients and, as such, they should be considered as preliminary, however, they indicate that the assessment of immune checkpoints on CTCs may promote our understanding of the mechanisms underlying immunotherapy resistance and that the investigated approach has the potential to address a critical unmet clinical need in non-small cell lung cancer patients treated with ICIs", the professor added.
ANGLE founder and chief executive Andrew Newland commented: "In addition to our key focus on securing FDA clearance for Parsortix, we are progressing the establishment of clinical laboratories so that we can offer laboratory-developed tests. The combination of PD-L1 and IDO assessment using Parsortix opens a major market opportunity for ANGLE in the key area of cancer immunotherapy, for a test which we can offer from our clinical laboratories."